|Committee Member||Employment||Consultant||Speaker's Bureau||Ownership/ Partnership/ Principal||Personal Research||Institutional, Organizational, or Other Financial Benefit||Expert Witness||Voting Recusals by Section⁎|
|Patrick T. O'Gara, Chair||Harvard Medical School—Professor of Medicine||None||None||None||None||None||None||None|
|Frederick G. Kushner, Vice Chair||Tulane University School of Medicine—Clinical Professor of Medicine; Heart Clinic of Louisiana—Medical Director||None||None||None||None||None|
|Deborah D. Ascheim||Mount Sinai School of Medicine—Associate Professor; InCHOIR—Clinical Director of Research||None||None||None||None||None||None||None|
|Donald E. Casey, Jr||Atlantic Health— Chief Medical Officer and Vice President of Quality||None||None||None||None||None||None||None|
|Mina K. Chung||Cleveland Clinic Foundation—Associate Professor of Medicine||None||None||None|
|James A. de Lemos||UT Southwestern Medical School—Professor of Medicine||None||None||None|
|Steven M. Ettinger||Penn State Heart & Vascular Institute—Professor of Medicine and Radiology||None||None||None||None||None||4.3.1|
|James C. Fang||University Hospitals Case Medical Center—Director, Heart Transplantation||None||None||None||None||184.108.40.206|
|Francis M. Fesmire||Heart Stroke Center—Director||None||None||None||None||8.3|
|Barry A. Franklin||William Beaumont Hospital—Director, Cardiac Rehabilitation and Exercise Laboratories||None||None||None||None||None||None||None|
|Christopher B. Granger||Duke Clinical Research Institute—Director, Cardiac Care Unit; Assistant Professor of Medicine||None||None||None||None|
|Harlan M. Krumholz||Yale University School of Medicine—Professor of Medicine||None||None||None||None||None||None|
|Jane A. Linderbaum||Mayo Clinic—Assistant Professor of Medicine||None||None||None||None||None||None||None|
|David A. Morrow||Harvard Medical School—Associate Professor of Medicine||None||None||None|
|L. Kristin Newby||Duke University Medical Center, Division of Cardiology—Professor of Medicine||None||None||None||None|
|Joseph P. Ornato||Department of Emergency MedicineVirginia Commonwealth University— Professor and Chairman||None||None||None||None||None|
|Narith Ou||Mayo Clinic—Pharmacotherapy Coordinator, Cardiology||None||None||None||None||None||None||None|
|Martha J. Radford||NYU Langone Medical Center—Chief Quality Officer; NYU School of Medicine—Professor of Medicine (Cardiology)||None||None||None||None||None||None||None|
|Jacqueline E. Tamis-Holland||St Luke's-Roosevelt Hospital Center— Director, Interventional Cardiology Fellowship Program; Columbia University, College of Physicians and Surgeons— Assistant Professor of Clinical Medicine||None||None||None||None||None||None||None|
|Carl L. Tommaso||Skokie Hospital—Director of Catheterization Laboratory; North Shore University Health Systems||None||None||None||None||None||None||None|
|Cynthia M. Tracy||George Washington University Medical Center—Associate Director, Division of Cardiology||None||None||None||None||None||None||None|
|Y. Joseph Woo||Hospital of the University of Pennsylvania—Associate Professor of Surgery||None||None||None||None||None||None||None|
|David X. Zhao||Vanderbilt University Medical Center—Director, Cardiac Catheterization and Interventional Cardiology||None||None||None||None||None||4.3.1|
This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. According to the ACCF/AHA, a person has a relevant relationship IF: a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) The company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) The person or a member of the person's household has a reasonable potential for financial, professional, or other personal gain or loss as a result of the issues/content addressed in the document.
ACS indicates acute coronary syndromes; DSMB, data safety monitoring board; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; and PI, principal investigator.
↵⁎ Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities could apply. Section numbers apply to the full-text guideline.
↵† No financial benefit.
↵‡ Significant relationship.
↵§ Dr. Ettinger's relationship with Medtronic was added just before balloting of the recommendations, so it was not relevant during the writing stage; however, the addition of this relationship makes the writing committee out of compliance with the minimum 50% no relevant RWI requirement.